Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HLF with free AI briefings, catalyst countdowns, and dilution alerts.

HLF · HERBALIFE LTD.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$409.2M Cash on Hand
CF+ Cash Runway
Follow HLF by email Get an email when HLF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HLF, unsubscribe in one click. Privacy

📣 What HLF Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

HLF holds $409.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HLF files for a raise →

👥 Who Owns HLF

Insiders 2.8% Institutions (346 holders) 97.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
BAUPOST GROUP LLC/MA Institution (13G, 5%+) 10,259,844 9.78% 2026-09-30
Nantahala Capital Management, LLC Institution (13G, 5%+) 6,953,653 6.63% 2026-03-31
Vanguard Portfolio Management Institution (13G, 5%+) 6,330,563 6.04% 2026-03-31
Michael Johnson
Director · +799,238 options
Insider 887,415 0.85% 2026-02-25
Robert Levy
President · +66,602 options
Insider 444,454 0.42% 2026-05-03
Des Walsh
Director
Insider 261,879 0.25% 2026-05-08
John DeSimone
Interim CEO · +124,983 options
Insider 241,144 0.23% 2026-02-16
Juan Miguel Mendoza
Director
Insider 181,879 0.17% 2026-05-08
Henry C Wang
Chief Legal Officer · +66,602 options
Insider 142,514 0.14% 2026-05-03
Donal L Mulligan
Director
Insider 128,982 0.12% 2026-05-08
Stephan Paulo Gratziani
Chief Executive Officer · +430,066 options
Insider 107,310 0.10% 2026-05-03
Maria Otero
Director
Insider 95,129 0.09% 2026-05-08

Share count 104,895,787 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HLF picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HLF and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.